Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Go back to Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis| Avalon Technology Group, Inc. (NASDAQ: AVLN) | Delayed: 32.97 +1.52 (4.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.45 | 52 Week High | $0.00 | |||
| Open | $31.71 | 52 Week Low | $0.00 | |||
| Day High | $33.19 | P/E | N/A | |||
| Day Low | $30.27 | EPS | $0.00 | |||
| Volume | 503,897 | |||||
